Work

Figure 3 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors

Year: 2025

Type: other

Abstract: Tumor burden changes. Of the 22 patients treated, 15 (68.2%) patients were evaluable for response.

DOI: 10.1158/1078-0432.30516496

Authors: Lillian L. Siu, Timothy A. Yap, Sofia Genta, Gregory Pennock, Christine Hicking, Deepthi S. Vagge, Jatinder Kaur Mukker, Giuseppe Locatelli, Anthony W. Tolcher

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4415786809

Cites:

Cited by:

Related to: